CClinicalTrials.gg
Status unknownNCT04763941CLIMERUpdated May 2, 2022

Clinical Dementia Rating Medical Record

An observational study in Clinical Dementia Rating (CDR) From the Analysis of Medical Record and Clinical Dementia Rating (CDR) Face-to-face Interview With the Patient, sponsored by Hospices Civils de Lyon. Status unknown at 1 site in France. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Hospices Civils de Lyon · Observational

The sponsor has not verified this record recently (last verified Jan 2022), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
144
Ages
65 Years and older
Sex
All
01

Study summary

The assessment of severity of the cognitive and functional impairment is essential in the follow-up of patients with neurocognitive disorders and in the assessment of the effectiveness of therapeutics. However, the systematic assessment of the Clinical Dementia Rating (CDR) scale is limited due to the time required to complete it (approximately 45 min to 1 hour). Insofar as studies have shown correspondences between the CDR and scales measuring cognitive and neuropsychological performance, and as part of memory consultations, several functional and neuropsychological scales are systematically administered, we wish to conduct a study validating the feasibility of the CDR based on information already available in the patient's file compared to the evaluation of the CDR by the usual method (face-to-face interview in consultation).

This study should highlight the feasibility of scoring the CDR-SB from the files of patients in memory consultation, first in terms of reliability of the scores obtained compared to the standard evaluation, and on the other hand in terms of organization and duration of administration.

02

Conditions studied

  • Clinical Dementia Rating (CDR) From the Analysis of Medical Record
  • Clinical Dementia Rating (CDR) Face-to-face Interview With the Patient

Keywords

  • CDR
  • memory consultation
  • patient's file
  • reliability
03

In context

Dementia

2,172 studies on the registry are indexed under Dementia; 540 are open to participants now.

This study's planned enrollment of 144 is below the median of 250 across 482 observational studies indexed under Dementia.

Browse Dementia studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,826 studies on the registry; 439 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will be conducted on the basis of the patient consulting in Memory Consultation, specifically with the information already collected in normal care and the MEMORA cohort.

Inclusion criteria

  • Patient who has CDR assessment in face-to-face interview during the memory consultation,
  • Patient with an isolated cognitive complaint or a neurocognitive disorder
  • Patient included in the MEMORA cohort

Exclusion criteria

Exclusion Criteria:

  • Patient or caregiver who does not wish their data to be used for research purposes within the framework of the MEMORA cohort.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
144 participants (estimated)
Patient registry
No

Groups and cohorts

  • Memory consultation patient

    The study will be conducted on the basis of the patient consulting in Memory Consultation, specifically with the information already collected in normal care and the MEMORA cohort.

    Diagnostic Test: CDR assessment face-to-face

Interventions

  • Diagnostic testCDR assessment face-to-face

    The assessment of the CDR is administered once by a psychologist with the patient and his caregiver.

06

What researchers measure

Primary outcomes

  1. CDR Sum of boxes (CDR-SB) score out of 18

    The CDR-SB score is obtained in normal condition and on file for the same patients. The CDR-SB score makes it possible to distinguish the following classes: 0 (normal), 0.5-4 (questionable cognitive impairment), 0.5-2.5 (questionable impairment), 3-4 (very mild major TNC or very mild dementia), 4.5- 9 (mild or mild dementia), 9.5-15.5 (moderate dementia), 16-18 (severe dementia). The patient's aptitudes are assessed in 6 different areas: 3 cognitive skills: memory, orientation and judgment, 3 acts of everyday living: participation in collective life, home occupations and hobbies, personal care.

    Time frame: The CDR-SB score is collected at the baseline.

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04763941
Lead sponsor
Hospices Civils de Lyon
Responsible party
Sponsor
First posted
Feb 21, 2021
Start date
Jan 1, 2020
Primary completion
Oct 1, 2020
Completion
Dec 31, 2022 (estimated)
Last update
May 2, 2022

Study contacts

Anthony Bathsavanis, Psy D
Contact
anthony.bathsavanis@chu-lyon.fr
4 72 432 206 ext. +33
Virginie Dauphinot
Contact
virginie.dauphinot@chu-lyon.fr
Anthony Bathsavanis, Psy D
study director · Hôpital des Charpennes
Pierre Krolak-Salmon, MD
principal investigator · Hopital Edouard Herriot

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion